Accelerate Diagnostics reports Q2 EPS ($2.36) vs. ($2.43) last year

Reports Q2 revenue $2.92M vs. $3.86M last year. “Throughout the quarter, we’ve significantly advanced our Wave Program,” stated Jack Phillips, CEO of Accelerate Diagnostics, Inc. “Our recent achievements underscore our commitment to delivering a Wave pre-clinical positive blood culture study by year-end. Moreover, we’re pleased with the ongoing progress of our BD partnership, resulting in the strongest quarter for US contracted instruments since 2021.”